张琰琴, 王芳, 丁洁. 儿童罕见肾脏病诊治现状及展望[J]. 罕见病研究, 2022, 1(3): 233-237. DOI: 10.12376/j.issn.2097-0501.2022.03.002
引用本文: 张琰琴, 王芳, 丁洁. 儿童罕见肾脏病诊治现状及展望[J]. 罕见病研究, 2022, 1(3): 233-237. DOI: 10.12376/j.issn.2097-0501.2022.03.002
ZHANG Yanqin, WANG Fang, DING Jie. The Status Quo and Prospects of Diagnosis and Treatment of Rare Kidney Disease in Children[J]. Journal of Rare Diseases, 2022, 1(3): 233-237. DOI: 10.12376/j.issn.2097-0501.2022.03.002
Citation: ZHANG Yanqin, WANG Fang, DING Jie. The Status Quo and Prospects of Diagnosis and Treatment of Rare Kidney Disease in Children[J]. Journal of Rare Diseases, 2022, 1(3): 233-237. DOI: 10.12376/j.issn.2097-0501.2022.03.002

儿童罕见肾脏病诊治现状及展望

The Status Quo and Prospects of Diagnosis and Treatment of Rare Kidney Disease in Children

  • 摘要: 儿童罕见肾脏病是导致儿童慢性肾脏病、肾衰竭的重要疾病构成,其中大部分是遗传性肾脏病,占儿童慢性肾脏病的29.7%~52.1%。近十多年以来,随着二代测序技术在临床的广泛应用,提高了儿童罕见肾脏病的诊断能力。2018年公布的中国《第一批罕见病目录》进一步全面推动和促进了中国儿童罕见肾脏病的诊治和研究,同时儿童罕见肾脏病的诊治也面临诸多挑战,如基因变异致病性判断、缺乏监测疾病进展的生物标志物、缺少治疗药物等。今后儿童罕见肾脏病的诊断和治疗需要患者、临床医生、药物研发企业以及政府不同部门的共同努力,进一步促进研究进展向临床应用的快速转化,以满足儿童罕见肾脏病患者的诊治需求。

     

    Abstract: Rare kidney diseases are important causes of chronic kidney disease (CKD) in children. The majority of rare kidney diseases in children are hereditary kidney diseases, accounting for about 29.7% to 52.1% of children with CKD. Next-generation sequencing has been widely used in clinical diagnosis in the past decade, leading to the improvement of the diagnosis of hereditary kidney diseases. In 2018, China announced the first list of rare diseases and greatly enhanced the diagnosis, treatment and research of rare diseases in China, including rare kidney disease. Meanwhile, China faces great challenges in the diagnosis and treatment of hereditary kidney diseases in Children, including the assessment of pathogenicity of gene variants, the lack of biomarkers for disease progression and therapy efficacy, lack of drugs, and others. The future lies in the cooperation between patients, physicians, researchers, and health policy markers, and the fast translation from research finding to clinical application, so as to meet the demand from the children with rare kidney diseases in China.

     

/

返回文章
返回